The patient was 54-year-old 
Introduction
It has been reported that several combination chemotherapies, such as PAC (cisplatin, doxorubicin, and cyclophosphamide) (1) and ADOC (doxorubicin, cisplatin, vincristine, and cyclophosphamide) (2, 3) , are effective for patients with locally advanced or recurrent thymomas. However, the standard treatment for recurrent cases already treated with PAC and ADOC remain controversial. Although there has been a few cases successfully treated with newly developed anticancer agents, such as paclitaxel (4) 
and docetaxel (5), there is not enough data to analyze whether or not these regimens can be justified as the standard treatment for patients with recurrent thymoma.
Recently, it has been reported that combined treatment with somatostatin (SST) analogue and prednisolone is effective for patients with recurrent thymoma (6) (7) (8) (9) (Fig. 3A) and thoracic CT (Fig. 3B) (14) .
F i g u r e 2 . Ch e s t r a d i o g r a p h r e v e a l e d mu l t i p l e n o d u l a r l e s i o n s i n t h e l e f t l u n g f i e l d ( 2 A) . T h o r a c i c c o mp u t e d t o mo g r a p h y ( CT ) r e v e a l e d mu l t i p l e d i s s e mi n a t e d p l e u r a l n o d u l e s ( 2 B ) .

A
Discussion
Octreotide is a synthetic octapeptide SST analogue, which acts for a longer period compared to the naturally occurring SST. SST is polypeptide hormone consisting of 14 amino acids and its receptors are expressed in various tissues, including hypothalamus, cerebral cortex, gastrointestinal tracts, pancreas, as well as the thymus (9-11). SST inhibits the release of the following hormones: growth hormone from the pituitary gland, glucagon and insulin from the pancreas, and gastrin, VIP (vasoactive intestinal polypeptide), and secretin from the gastrointestinal tracts, thyroid releasing hormone and so on. Among the five kinds of SST receptors (SST1 to 5), SST2 is generally identified in various human tumor tissues (12, 13). Additionally, octreotide is known to have strong affinity to SST2 and SST5 receptors. Secretion of SST is result of the binding of octreotide to the SST receptor, however, it does not bind to the receptors of the normal thymic epithelial cells. To support this, octreotide has a direct anti-tumor effect for several cancer cell lines, including breast cancer and gastric cancer
Although the detailed mechanism of the anti-tumor effect (15) , several similar cases have been reported in the literature (6, 8) . However, the detailed mechanism of the synergy effect of prednisolone with octreotide remains unclear. In the present case, anti-tumor effect of octreotide was not sufficient and an additional administration of prednisolone appeared to be effective. Most cases describing the dramatic response of thymomas to glucocorticoid alone are classified B1 subtype, which contain numerous lymphocytes (16, 17 In the present case, the dosage of both of octreotide and prednisolone was lower than that used in the previous phase II study (6 (6) (7) (8) (9) . However, it has been shown that 92.9 (6) -100% (21) of these patients with thymoma revealed positive uptake with SST receptor scintigraphy. Moreover, findings of the scintigraphy would be independent of the subtypes of thymic tumors (7, 20) . The usefulness of the scintigraphy in predicting the clinical response to octreotide treatment is still controversial in patients with various tumors, including malignant neuroendocrine tumors, pituitary adenoma, and pancreatic carcinoma (22) . The response rate of octreotide has not been reported in patients with thymoma, revealing negative uptake with SST receptor scintigraphy. Thus, considering the present situation in Japan, we commenced octreotide therapy without performing SST receptor scintigraphy after obtaining informed consent since it is difficult for the patient to undergo further systemic chemotherapy.
F i g u r e 3 . Af t e r s e v e n mo n t h s o f t r e a t me n t wi t h o c t r e o t i d e a n d p r e d n i s o l o n e , b o t h c h e s t r a d i o g r a p h ( 3 A) a n d CT ( 3 B ) r e v e a l e d a ma r k e d d e c r e a s e i n s i z e o f t h e p l e u r a l t u mo r s .
A
B of octreotide for thymomas is not fully understood, it has been reported that SST has antiproliferative effects associated with 1) inhibition of growth factors, such as insulin-like growth factor-1 (IGF-1) and epidermal growth factor (EGF), 2) activation of immunity and 3) inhibition of tumor vessel angiogenesis (14). Since Palmieri G et al first reported the effectiveness of the combined treatment of octreotide with prednisolone in 1997
In conclusion, the present case demonstrated that combined therapy with octreotide and prednisolone is to be considered as an effective and tolerable treatment in patients with refractory recurrent thymoma.
